All the latest worldwide HIV and AIDS news, including treatment, prevention, and hepatitis and TB co-infections. News from our own team of writers plus articles we have selected from other sources.

aidsmap hiv & aids news


← First12345...714Next →

hiv & aids news selected from other sources

  • Transmission and prevention
    European Advocates Engage with Biomedical Prevention
    AVAC | 3 hours ago

    The European AIDS Treatment Group and AVAC organized an unprecedented three-day workshop: New Developments in HIV Prevention. See for more. In addition to comprehensive updates on product pipelines across the prevention research landscape, the group discussed the anticipation of the first data from European oral PrEP trials and the implications for PrEP access in Europe.

  • Bad science and bogus treatments
    Déjà Vu – Claims of HIV Cures and Re-Treading Old Ground
    Nigeria Health Watch | 4 hours ago

    A few days ago while in Abuja, I was surprised to hear the news presenter announce that a Federal High Court had “lifted the ban” on Dr Abalaka’s “vaccine” against HIV. I was struck by a number of things – an abiding discomfort at the quality of reporting on science and health matters in the Nigerian media; a sense of guilt that, in failing to tell our stories, younger Nigerians are at risk of repeating missteps of the past; and a fear that many, misled by the news item, may put their lives at risk.

  • Viral load
    An HIV Doctor Tells You If Undetectable Really Is the New Negative
    The Body | 5 hours ago

    Does being undetectable change the way you talk about your HIV status? Can a person who is undetectable stop worrying about transmitting HIV? Joel Gallant, an HIV doctor at Southwest CARE Center in Santa Fe, New Mexico gives his view.

  • Neurological and cognitive problems
    Antiretroviral Neurotoxicity May Cause Cognitive Problems
    The Body Pro | 5 hours ago

    As many as 50% of those on combination antiretroviral therapy (cART) suffer from mild to moderate cognitive dysfunction. Antiretroviral medications themselves may be partly to blame for such neurocognitive problems, suggests a recent review of previous studies. But the authors of this review do not recommend that antiretroviral treatment be stopped.

  • Behaviour change interventions
    Condom advert – HIV prevention or infidelity promotion?
    Key Correspondents | 27 January 2015

    Controversy over an advert on condom use to prevent HIV among married couples led by a cross section of Kenyan religious leaders has left many HIV activists astonished at the ‘denial of reality’.

  • HIV and criminal law
    Military justice?
    Positive Lite | 27 January 2015

    An extraordinary example of HIV criminalization gone awry in the States. Bob Leahy talks to Lt. Colonel Ken Pinkela, court martialed and sentenced to a jail term for allegedly exposing another officer to HIV, when no sexual contact occurred, says Pinkela.

  • Relationships and feelings
    How to Talk to Your Partner About Using PrEP
    HIV Plus | 27 January 2015

    Talking about PrEP with your partner can open up a can of worms. Here's how to make the conversation as smooth as possible.

  • Access to medicines and treatment
    MSF response to Gilead announcement on inclusion of hepatitis C drug GS-5816 in voluntary licence
    Médecins Sans Frontières press release | 27 January 2015

    GS-5816 is an important anti-hepatitis C compound that, in combination with sofosbuvir, will greatly simplify treatment for developing countries. However, it appears that none of the terms and conditions of the original licence agreement has been changed, meaning that the concerns that MSF has with the licence agreement remain, including the limited geographic scope of the agreement, restrictions on the production and export of active pharmaceutical ingredient, and the inclusion of an ethically and medically controversial and problematic anti-diversion clause.

  • New and experimental hepatitis C treatment
    Gilead Expands Hepatitis C Generic Licensing Agreements to Include Investigational Pan-Genotypic Agent
    Gilead press release | 27 January 2015

    Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the company has expanded its hepatitis C generic licensing agreements to include the investigational NS5A inhibitor GS-5816, which is being evaluated in Phase 3 clinical studies as part of a single tablet regimen that combines the compound and sofosbuvir for the treatment of all six genotypes of hepatitis C. The expanded agreements will allow Gilead’s India-based partners to manufacture GS-5816 and the single tablet regimen of sofosbuvir/GS-5816, once approved, for distribution in 91 developing countries, which together account for 54 percent of the total worldwide population of individuals infected with the hepatitis C virus (HCV).

  • Recreational drug use
    Managing crystal meth: tina and gay men
    Archer | 26 January 2015

    “I’m being destructive, and I know it.” This statement comes from community consultation I did recently with HIV-positive gay men on how they feel they’re being affected by using crystal meth, otherwise known as ice, or tina in the queer community.

← First12345...1000Next →

Hepatitis C news

WHO recommends global use of newest hepatitis C drugs, urges price reductions.

HIV update

Sign up for HIV update, our fortnightly news bulletin for people living with HIV in the UK.

Treatment as prevention

No-one with an undetectable viral load, gay or heterosexual, transmits HIV in two years of PARTNER study.

aidsmap news apps

Download the free aidsmap news iPhone and android apps.